Roland Neuhaus

Berlin, BE 13353, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor.

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor.

Journal: Journal of medicinal chemistry

Published: October 25, 2024

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

Journal: Journal of medicinal chemistry

Published: September 27, 2024

BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe.

BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe.

Journal: Journal of medicinal chemistry

Published: October 19, 2022

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Journal: Journal of medicinal chemistry

Published: April 28, 2020

Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.

Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.

Journal: Bioorganic & medicinal chemistry letters

Published: March 25, 2020

Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles.

Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles.

Journal: Nature chemical biology

Published: August 20, 2019

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Journal: Molecular cancer therapeutics

Published: December 18, 2017

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Journal: ACS chemical biology

Published: July 06, 2017

Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death.

Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death.

Journal: Cell death & disease

Published: December 19, 2016

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Journal: Leukemia

Published: December 16, 2016

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Journal: Acta neuropathologica

Published: December 13, 2016

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Journal: ChemMedChem

Published: May 31, 2016

Showing 1-12 of 25

Last Updated: 09/26/2026